Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects - Full Text View

Purpose

The original study executed between 2002-2004 was an interventional trial in which 20, healthy, normal-weight female subjects were randomized to a four-day fast plus daily subcutaneous injections of leptin or a four day fast plus daily subcutaneous injections of a placebo. The primary endpoints were gonadotropin pulsatility, TSH secretion and thyroid function, and cortisol secretion. The current study is a secondary analysis focussed on the placebo group which underwent a four-day fast. The study is looking at the effects of fasting on gut-derived hormones and inflammatory markers in healthy, normal-weight women. The hypothesis for this secondary analysis was that four days of fasting would augment levels of orexigenic gut-derived hormones and suppress levels of anorexigenic gut-derived horomones, while suppressing secretion of inflammatory cytokines.

Condition	Intervention
Healthy	Drug: Leptin administration Behavioral: Fasting


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator)
Official Title:	Effects of Four-day Fast on Gut-derived Hormones and Inflammatory Markers in Healthy, Normal-weight Women.

Resource links provided by NLM:

MedlinePlus related topics: Hormones

U.S. FDA Resources

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:

Hormone levels change from baseline. [ Time Frame: Change from baseline after 4 days of intervention. ] [ Designated as safety issue: No ]
Original study looking at gonadotropin pulsitility, TSH secretion and thyroid function, and cortisol secretion. Present study looking at gut-hormone secretion.

Secondary Outcome Measures:

Levels of inflammatory cytokines change from baseline. [ Time Frame: Change from baseline after 4 days of intervention. ] [ Designated as safety issue: No ]


Enrollment:	20
Study Start Date:	November 2002
Study Completion Date:	December 2003
Primary Completion Date:	December 2003 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Fasting alone	Behavioral: Fasting Complete fasting, save for water and multivitamin, for four days.
Active Comparator: Fasting plus leptin	Drug: Leptin administration Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days. Behavioral: Fasting Complete fasting, save for water and multivitamin, for four days.

Eligibility


Ages Eligible for Study:	18 Years to 35 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

female age 18-35
BMI 20-26.0
eumenorrheic with normal FSH, TSH, Prolactin
Hgb > 12 g/dL, normal creatinine
normal puberty and development
negative pregnancy test. In addition, subjects agreed not to be sexually active during the course of the inpatient study and to use contraception for a period of 48 hours after discharge from the hospital.

Exclusion Criteria:

medical or endocrine problems known to affect thyroid, reproductive, GH or cortisol function
medications known to affect neuroendocrine function
prior history of eating disorder or significant menstrual irregularities
subjects who have a known hypersensitivity to E. Coli derived protein.
subjects with a history of seizure disorder, significant cardiac disease, medication for cardiac disease, or kidney disease
history of anaphylaxis or anaphylactoid like reactions.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01257841

Locations


United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Massachusetts Institute of Technology
Cambridge, Massachusetts, United States, 02139

Sponsors and Collaborators

Massachusetts General Hospital

Massachusetts Institute of Technology

Investigators


Principal Investigator:	Steven K Grinspoon, MD	Massachusetts General Hospital

More Information

Publications:

Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M, Grinspoon S. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab. 2005 Oct;90(10):5779-85. Epub 2005 Aug 2.

Schurgin S, Canavan B, Koutkia P, Depaoli AM, Grinspoon S. Endocrine and metabolic effects of physiologic r-metHuLeptin administration during acute caloric deprivation in normal-weight women. J Clin Endocrinol Metab. 2004 Nov;89(11):5402-9.

Koutkia P, Schurgin S, Berry J, Breu J, Lee BS, Klibanski A, Grinspoon S. Reciprocal changes in endogenous ghrelin and growth hormone during fasting in healthy women. Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E814-22. Epub 2005 Jun 21.


Responsible Party:	Steven K Grinspoon, M.D. Professor of Medicine, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT01257841 History of Changes
Other Study ID Numbers:	2002P-000518SA1
Study First Received:	December 7, 2010
Last Updated:	December 9, 2010
Health Authority:	United States: Data Safety Monitoring Board, Massachusetts General Hospital United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:


Fasting Gut hormones Inflammatory Cytokines

ClinicalTrials.gov processed this record on March 03, 2015